How Mounjaro prescribing works in the UK

You've decided to ask about Mounjaro, here's what a prescriber actually reviews

Picture this: you fill in a consultation form late on a Tuesday evening and wonder what happens next. The answer is that a real prescriber (a GPhC-registered Independent Prescriber, not a screening algorithm) reads your answers the following morning, usually well before noon. Tirzepatide GP prescribing, whether through a private service or increasingly through NHS primary care, always starts the same way: a clinician evaluates the whole picture, not just a single number.

That picture includes your current BMI, any weight-related conditions (such as hypertension, dyslipidaemia, type 2 diabetes, or obstructive sleep apnoea), your medication list, and any contraindications listed in the NHS tirzepatide guidance. Relevant history (pancreatitis, medullary thyroid carcinoma, MEN2, significant gastrointestinal conditions) must be disclosed and assessed. A borderline BMI, a complex medication list, or an undisclosed condition can and should change the outcome. Prescribers are not gatekeepers trying to block access; they are clinicians managing risk. Those two things can look the same from the outside, but they are not.

For more on what the licensed prescribing criteria actually say, the Mounjaro prescribing information page covers the SmPC requirements in detail.

What the prescribing guidelines say about dose and titration

The licensed UK schedule starts at 2.5 mg. That first pen exists primarily so your body adjusts to the medicine gradually, reducing the likelihood of early nausea. The prescriber then titrates upward (typically in 2.5 mg steps at roughly four-week intervals) based on tolerability and response. The maximum licensed dose is 15 mg. At no point should a patient be self-directing their own titration; the prescriber owns those decisions, informed by what the patient reports between reviews.

NICE's appraisal of tirzepatide, TA1026, sets the clinical threshold for continuing treatment: if a patient has not achieved at least 5% weight loss after six months at the highest tolerated dose, a prescriber should review whether to continue. This is built into responsible prescribing practice, not left to chance. The UK prescribing guidelines page unpacks these criteria further if you want the full regulatory detail.

Dose increases are not cosmetic milestones. Each step carries an adjusted side-effect profile. Women using oral contraceptives need to add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide slows gastric emptying and can affect pill absorption. That is a prescribing consideration, not a footnote, a good prescriber raises it proactively.

NHS prescribing versus private prescribing: what's different

Since April 2026, GP practices in England may prescribe tirzepatide under the new QOF contract, though participation is optional and availability varies considerably by practice and area. NHS prescribing sits within NICE TA1026's phased cohort structure: from June 2025, patients with a BMI of 40 or above plus four or more qualifying conditions became eligible; from June 2026, the BMI threshold expanded to 35 for that same cohort. Even when a patient meets the criteria on paper, NHS access depends on local commissioning and a wraparound diet-and-activity support programme. For many people, the waiting reality does not match the eligibility reality. Our guide to GPs prescribing Mounjaro covers the NHS primary-care rollout in more depth.

Private prescribing follows the licensed SmPC rather than the NHS commissioning criteria. That means a prescriber can issue a private prescription for an adult with a BMI of 30 or above (or 27 with a qualifying condition), assessed as clinically suitable, without the patient needing to meet the NHS's four-comorbidity threshold. The prescriber's duty of care is identical (full assessment, documented clinical reasoning, regular review) but the eligibility floor is lower. If you want to understand what the private route costs alongside what is clinically involved, the Mounjaro price and cost page sets out the private-prescription context honestly.

At nume (a GPhC-registered online pharmacy) orders placed by 12pm on weekdays are reviewed the same day by one of our prescribers. If approved as clinically suitable, treatment is dispatched that afternoon, arriving with DPD the next working day. That is the 12pm cut-off worth knowing about if timing matters to you.

Repeat prescribing and long-term clinical oversight

Prescribing tirzepatide is not a one-off transaction. Every repeat order requires a clinical re-review, current weight, any side effects, medication changes, and whether the dose increase is warranted. At nume, that review happens before every dispatch. There are no subscriptions and no automatic renewals; a prescriber reads each repeat request as a fresh clinical decision. For patients transferring from another provider, evidence of their current dose and treatment history is required before a prescriber will continue at a higher dose.

The tirzepatide overview covers how the medicine works pharmacologically, while our Mounjaro pillar page links out to the full range of clinical topics. If a specific question about your situation has come up (interactions, travel, or anything else outside the standard pathway) our FAQ page is a useful starting point, and our prescribers are reachable through the contact page seven days a week.